Insider Selling: NIOX Group (LON:NIOX) Insider Sells £3,609.60 in Stock

Key Points

• Insider Nicholas Mills sold 4,512 NIOX Group shares on October 27 at an average price of GBX 80, for proceeds of £3,609.60.
• NIOX shares rose 0.3% to GBX 64.60 in Wednesday midday trading, below the 50-day moving average of GBX 67.34.
• The company reported quarterly EPS of GBX 1.41, with a 14.74% net margin and 10.01% return on equity.

NIOX Group Plc (LON:NIOX - Get Free Report) insider Nicholas Mills sold 4,512 shares of the stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of GBX 80, for a total value of £3,609.60.

NIOX Group Trading Up 0.3%

NIOX Group stock traded up GBX 0.20 during midday trading on Wednesday, reaching GBX 64.60. The stock had a trading volume of 281,066 shares, compared to its average volume of 902,221. The company has a quick ratio of 1.94, a current ratio of 4.60 and a debt-to-equity ratio of 1.06. The company has a fifty day moving average of GBX 67.34 and a 200 day moving average of GBX 63.13. NIOX Group Plc has a 52-week low of GBX 53.84 and a 52-week high of GBX 80. The firm has a market cap of £271.88 million, a price-to-earnings ratio of 39.63 and a beta of 0.92.

NIOX Group (LON:NIOX - Get Free Report) last posted its quarterly earnings results on Wednesday, September 30th. The company reported GBX 1.41 EPS for the quarter. NIOX Group had a net margin of 14.74% and a return on equity of 10.01%. On average, analysts anticipate that NIOX Group Plc will post 1.17 earnings per share for the current fiscal year.

NIOX Group Company Profile

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. Headquartered in the UK and listed on the London Stock Exchange ticker: NIOX, the company operates internationally, serving healthcare professionals in over 50 countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.